Life Sciences Archive » May, 2020

Life Sciences - May, 2020

369 articles

• Mylan Gets More Sanofi Insulin Pen Patents Nixed At PTAB
• FDA Seeks Orange Book Feedback As Drug Guide Turns 40
• Dems Ask Pentagon How It's Spending $10.6B In Virus Funds
• Cannabis Bill Roundup: La. May Expand Medical Pot Access
• COVID-19 IP Catch-Up: Remdesivir Access, Zoom TM Security
• COVID-19 Securities Catch-Up: The 8 Biggest Investor Actions
• AdventHealth Sues Attorney Over Failed $57.5M Masks Deal
• Fed. Circ. Backs PTAB Trim Of Boston Scientific Spine Pain IP
• Fla. Tells State High Court Medical Pot Statute Is Lawful
• Trump Says US Exiting WHO Over COVID-19 Response
• Tax Incentives May Not Spur US Operations In Virus Fight
• Feds Fight Pharmacists' Bid To Ax Opioid Indictment
• Gov't Contracts Of The Month: Virus, Space And Google Deals
• Columbia Care Accused Of Plot To Steal Fla. Pot License
• Avoiding Inadvertent Privilege Waivers In E-Communications
• Incentives And Risks From OTC Drug Monograph Revamp
• Medical Tech Co. Looks To Dodge Investor Suit Over Backlog
• 5 Tips For Drafting Effective Legal Billing Guidelines
• Pharma Suppliers Appeal CMA Action Over UK Market Rig
• Pet Products Maker Accused of Monopolizing Online Market
• IP Owners Approach USPTO Evidence Proposal With Caution
• Assessing The Novel Antitrust Claims In Humira Case
• Lye Makers Want Out Of National Consolidated Antitrust Suit
• 10th Circ. Revives Genentech Cancer Drug Dosage Suit
• PTAB Takes Up 1 Of 2 Gilead Challenges To State Univ. Patent
• 3 Firms Steer Oncology Biotech's $350M Spinoff, IPO Plans
• Ex-USPTO Head, Retired Judge Back China Pharma IP Reform
• Express Scripts Loses Bid To Probe Emails In Antitrust Case
• Pediatric Home Care Giant Aveanna Hit With Data Breach Suit
• DOJ Says BigLaw Firms Put FBI Agent At Risk Of COVID-19
• Pharma Cos. Slam Cert. Bid In Diabetes Drug Price-Fixing Suit
• NJ Court Challenged Over Prolonged Sealing Of FCA Cases
• 2 Accused PED Suppliers Deny Horse Doping Charges
• Investor Sues Qiagen To Block $11.5B Thermo Fisher Deal
• FDA Asks Full DC Circ. To Undo Eagle's Orphan Drug Win
• Indian Generic Pharma Co. Can't Get $500M Award Nixed
• Don't Cancel Your Summer Associate Programs
• Tech Will Play Key Role In Real Estate's Road To Recovery
• Avoiding M&A Deal-Breaking Disputes During A Downturn
• Early Securities Litigation Trends Stemming From Recent IPOs
• Dems Press Pompeo For Info On Russian Ventilator Purchase
• EU Waives Fix For Takeda's £46B Shire Deal
• Gibson Dunn Guides Gene Test Co.'s IPO Amid COVID Slump
• Bipartisan Bill Proposes $100B In New Tech Funding
• Activists Say Gov't Should Have Rights To Remdesivir Patents
• Nonprofit Battelle Says Ex-Employee's FCA Suit Is Hollow
• Investors Say AmerisourceBergen Knew About Drug Scheme
• Ark. Harvest Health Affiliate Must Drop Name Amid TM Row
• La-Roche Can't Shake Class Cert. In Environmental Suit
• Car Ruling Bolsters Dicamba Punitive Damages, Farm Says
• Biotech Working On COVID-19 Therapies Raises $105M
• Ohio Counties Hit Pharmacies With Opioid Nuisance Claims
• Dispensary Tells 9th Circ. Pot Biz Tax Law Is Unconstitutional
• Sorrento Sued Over COVID-19 'Cure' Comment To Fox News
• 5 Ways To Reduce Post-Pandemic Legal Malpractice Exposure
• Sanofi To Raise $11.1B In Sale Of Regeneron Stake
• Biotech Pursuing COVID-19 Vaccine Inks $167M Acquisition
• Leaving The Tort System Behind Via Corporate Risk Transfer
• Trade Groups Join Chamber's Push For Virus Liability Shield
• Gilead Forges $375M 10-Year Partnership With Biopharma Co.
• Taiwan Antitrust Agency Clears Mylan, Pfizer Unit Deal
• $750M Namenda Deal OK'd But 21% Atty Fee Request In Doubt
• Pfizer, Mylan Can't Quickly Appeal EpiPen RICO Class Cert.
• 3 Highlights As HHS Watchdog Voices Concern On Meddling
• Full Fed. Circ. Asked To Abolish Assignor Estoppel Rule
• Drug Cos. Seek To Exit Chicago Opioid Case
• DNA Engineering Co. Codexis Sues Rival For TM Infringement
• Haynes And Boone To Open Office In San Francisco
• Health-Focused Firms Flood IPO Market With Fresh Filings
• Accused PPE Fraudsters Deny NY Price-Gouging Charges
• Immigrant Doctor Says Merck Can't Nix Suit Over Revoked Job
• High Court Won't Review GE, Teva Patent Appeals
• A Guide To Evaluating And Advertising COVID-19 Products
• Credibility Concerns About Virtual Arbitration Are Unfounded
• Shkreli, Vyera Look To Duck Monopolization Claims
• Suit Over 'Illegal' CBD Products Paused To Await FDA Rules
• Coronavirus Regulations: A State-By-State Week In Review
• Goodwin, MoFo Guide Fibrosis Biotech's $90M IPO Plans
• High Court Won't Review Nonconsensual Ch. 11 Releases
• Mallinckrodt Wants More Cuts To Seizure Drug Price Suit
• Medical Co. To Buy Solara, ActivStyle Suppliers For $487M
• Insitro Announces $143 Million Raised In Series B Financing
• Law360 Reveals Titans Of The Plaintiffs Bar
• Amerisource Hid 'Pillbillies' Email In Opioid MDL, Attys Say
• COVID-19 IP Catch-Up: Courts Divided On Getting IP To Trial
• Akorn Gets OK To Tap Into $30M Ch. 11 Funds
• CBD Trade Secret Suit Axed Over Hemp Co.'s Lack Of Counsel
• FDA Approves Hikma's Generic Vascepa Amid Fed. Circ. Fight
• Pfizer, Ranbaxy Sued Over Delay Of Generic Lipitor
• The Current Barriers To International Health Cooperation
• Justices Told Not To Hear Doctrine Of Equivalents Challenge
• FTC Tells 50 More Marketers To Stop Making COVID-19 Claims
• Austrian Manufacturer Wants Out Of Medicare Scheme Suit
• Mintz Bid To Win Malpractice Suit 'Fatally Flawed,' Lab Says
• Surescripts Can't Take FTC Monopoly Case To DC Circ. Yet
• Latham-Led Medical Device Maker Prices Upsized $156M IPO
• The Regulatory Pathway To A Vaccine For COVID-19
• Latham-Led Biopharma Co. Gets $15M For COVID-19 Vaccine
• A Lawyer's Guide To Client Service Continuity Planning
• Increasing Fed. Circ. IPR Appeals Are Shaping Patent Law
• Goodwin Group Combines Life Sciences, Real Estate Attys
• 3 Ways The Pandemic Has Changed How IPOs Are Done
• Michigan Vape Ban Injunction Upheld At Appellate Court
• CBD Co. Issues Recall After FDA Warning Letter
• Chanel Hit With Suit Linking Mesothelioma To Talc Products
• How Pandemic-Related Delays Affect Hatch-Waxman Litigants
• Maximizing Defense Advantages In Jurisdictional Discovery
• Investor Says Elanco Hid Inventory Woes In COVID-19 Bulletin
• Judge Finds Invisalign Maker Can't Dodge Monopoly Claims
• Drug Buyers' Retooled $34M Celgene Deal Wins Initial OK
• Virtual Meetings Could Be Fertile Ground For Legal Discovery
• InfoBionic Asks If Premature Alice Ax Doomed Invalidity Bid
• Former Danaher Exec Dodges Trade Secret, Contract Claims
• Fertility Chain IntegraMed Files For Ch. 7 After $7M Asset Sale
• Akorn Heads Into Ch. 11 For Sale With More Than $1B In Debt
• States Join Bid For Virus Delay In Purdue Pharma Bankruptcy
• Canadian Pot Co. Sundial Escapes NY Securities Suit
• Imerys Slams J&J's Bid To 'Seize Control' Of Its Ch. 11
• 4 Things To Know About Plan To Speed COVID-19 Patent Apps
• Advocacy Groups Decry New Trump Deregulatory Move
• Biopharma Co. Nets $120M To Research Quality Control Tech
• Indicted Generic-Drug Exec Wants Case Tried In New York
• Contingent Fees A Great Option For Cos. During Downturn
• The Role Of Remote Mediation After The Crisis Is Over
• AbbVie Says Recent Antitrust Ruling Irrelevant In Humira Case
• What ITC Means By 'Nexus' In Domestic Industry Test
• Fed. Circ. Urged To End 'Unrealistic' Obviousness Test
• New Info Could Boost Allergan ERISA Suit, 3rd Circ. Told
• NY Judge Won't Require In-Person Testimony In IP Bench Trial
• Compliance Tips For Running Clinical Trials During COVID-19
• US-Based Merck Banned From Using 'Merck' Trademark In UK
• Wachtell-Led Swiss Pharma Co. Raises $340M In Offering
• 7 Steps To Romancing The Virtual Classroom
• Broad, UC Each Tell PTAB It Invented CRISPR First
• US Rebukes Patent, Abortion Language In WHO Resolution
• J&J Unit Must Face Class Claims Over 'Rapid Release' Tylenol
• Imprisoned Pharmacist In No Extra Virus Danger, Feds Say
• Arbitrator Right To Dissolve Pot Partnership Forged In Fraud
• J&J To Stop Talc Sales In North America
• Cannabis Co. Seeks Nix Of Suit Over Scheme To Devalue Rival
• Global Economic Recovery Calls For Trade Policy Overhaul
• Main Street Lending Adjustments Mean Help For More Cos.
• Perceptive Advisors' Blank Check Co. Targets $125M IPO
• Coronavirus Regulations: A State-By-State Week In Review
• 5 Tips For Emergency Relief Petitions During COVID-19
• Key Return-To-Work Considerations For Law Firms
• Biopharma Company Rakes In $145M In Fundraising Effort
• Ropes Leads Cowen Healthcare Investments To $493M Fund
• Mylan Pushes For Mediation In EpiPen Antitrust Suit
• Otsuka Beats Abilify User's Failure-To-Warn Suit In Calif.
• Full Fed. Circ. Skips 1-Line Orders In Apple, Hearing Aid Cases
• 1-800 Contacts To Pay $15M To Exit Consumer Antitrust Case
• Latham-Led Medical Device Maker Inari Launches $110M IPO
• Onshoring Incentives Have Bipartisan Allure In Virus Bill Talks
• J&J Argues For Immunity In $57M Pa. Pelvic Mesh Appeal
• Hong Kong Index To Permit Cos. With Unequal Voting Shares
• German Lab Accused Of Illegally Selling Tick Test Kits In US
• Chancery Sees No Bias Caused By Bouchard In Meso Suit
• 9th Circ. Won't Revive J&J Breast Implant Suit
• A Creative Solution For Teaching Local Practice In Law School
• Bayer Foe Says Emailing Arnold & Porter Counts As Service
• Identifying Antitrust 'Safety Zones' During The Pandemic
• Dr. Reddy's $9M Deal Gets Nod In Quality Control Suit
• Ex-Theranos Exec Wants April 2021 Trial And His Passport
• Supreme Court Still Not Interested In 1-Line Fed. Circ. Orders
• Cell Therapy Company Raises $65M In Funding Round
• Shkreli Release Denied After 'Delusional' Virus Cure Boast
• Pandemic-Bruised IPO Market Shows Signs Of Healing
• Texas Agency Relaxes Guidelines For Controversial Sterilizer
• Europe Authority Bans Patents On Plants And Animals
• HHS Says Gilead Can't Allege Misconduct In HIV Drug IP Suit
• Talc Supplier Imerys Sets Ch. 11 Plan To Resolve Injury Claims
• 3M Settles Price-Gouging Trademark Case In Florida
• Cancer-Focused Biotech's Shares Soar After Upsized IPO
• Supplement Co. Banned From Hawking Fake COVID-19 Cures
• Why Gilstrap Is Getting Ready For Trial — And Not On Zoom
• Bayer, Merck Say Leg Amputation Suit Filed Too Late
• Implied Conflict Preemption May Apply In COVID-19 Cases
• Making Law Firm Panels Work For The Cost-Conscious GC
• How USPTO Examiner Type Affects Patents: Part 1
• #MeToo's Unexpected Implications For Shareholder Litigation
• Ex-Shook Hardy Trial Lawyer Joins Eckert Seamans In Pa.
• 7th Circ. Won't Rethink Allowing National Class In Ill. Fax Suit
• Health Hires: Polsinelli, DLA Piper, Eckert Seamans
• Fed. Circ. Revives Part Of Hearing Aid Patent Challenge
• FDA Warns Of Accuracy Issues With Abbott COVID-19 Tests
• Veeva Slams IQVIA's Sanctions Bid As 'Hyperbolic'
• COVID-19 IP Catch-Up: Source Code Woes, Generic Antivirals
• Pharma Co. Must Face Fraud, Trade Secret Claims In Drug Suit
• Flood Of Medical Funds May Hold Risks For New Contractors
• Sinovac Investor Settles SEC Disclosure Claims For $290K
• Trump Administration Threatens Veto Of Dems' $3T Relief Bill
• FDA Warns Allergan Over Breast Implant Studies
• Conn. Man Ran $2M Liquid Purification Tech Scam, SEC Says
• UCann's CBD Health Claims Must End Ch. 11, Creditor Says
• Tribes Urge Justices To Keep ACA's Indian Health Measures
• Pot Group Urges Legalization To Hike Tax Revenue Amid Virus
• How COVID-19 Is Affecting Drug Supply Regulation
• Voir Dire Tips For Preserving Defense-Friendly Jurors
• Pandemic Presents Teamwork Test For Law Firms
• Trump Moves To Fill Stockpile Ahead Of Next Virus Outbreak
• Highlights From The Virtual Antitrust Spring Meeting: Part 2
• No Bellwether For Diabetics In Insulin Case Despite Virus Risk
• Ex-Vaccine Chief Says Time Running Out For Virus Strategy
• Biogen Thwarts 'Brazen' Drug Copycat With IP Settlement
• Coronavirus Q&A: Arnold & Porter's Chair Of Health, Life Sci
• SEC Targets 2 Cos. Over Misleading COVID-19 Claims
• 1st Circ. Upholds Sanofi's Quick Win Against Age Bias Suit
• NY AG Gets Green Light For Subpoenas Into Sackler Finances
• Don't Bet On Aug. Trial In CVS Drug-Pricing Suit, Judge Says
• Officials Say China Backing Hacks On US Vaccine Research
• CVS Unit To Pay $15M Over 'Improper' Opioid Dispensing
• Natera, Illumina Ink Deal To End Row Over DNA Testing IP
• Judge Slams Andrus Wagstaff's Bid To Dodge Mesh Fee Share
• 9th Circ. Says Calif. Health Exchange Must Face Abortion Suit
• 9 Firms Vie For Lead Counsel In Inovio COVID-19 Vaccine Suit
• Investor Sues Over Nutraceutical's $446M Take-Private Deal
• 8 Tips For Retaining An Expert During COVID-19 And Beyond
• COVID-19 Underscores Diagnostic Patent Eligibility Problems
• 4 Personal Jurisdiction Questions Defendants Should Ask
• MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent
• Monsanto Can't KO Former Worker's Sex Discrimination Suit
• 1-800 Contacts Settles Search Term Class Action
• Gilead Inks Deals With Generic Cos. To Make COVID-19 Drug
• Paul Hastings, Baker Botts Drive $400M Animal Health Deal
• 3 Highlights As Senators Debate Reopenings Amid COVID-19
• Sens. Say Safety Regs Must Precede COVID-19 Biz Immunity
• Merck Aims To Revive Suit Over NJ Town's Zoning Changes
• FEMA Rule Sets New Standards For Priority Medical Contracts
• US Trustee Says Past Pot Biz Enough For Ch. 11 Dismissal
• Veeva Escapes IQVIA's Suit Over Noncompetes
• Zantac Makers Say Drug Has No Cancer Link As MDL Opens
• Conn. Asks Justices To Pass On Drug Price-Fixing Discovery
• Ecolab Accused Of Hiding Health Risks In Its Disinfectants
• What It's Like To Move From Army JAG To BigLaw
• SG Says Due Process Challenge To Retroactive IPRs Fails Too
• Pharma Supply Agreement Considerations During COVID-19
• Expect EPA Scrutiny Of COVID-19 Product Claims
• Coronavirus Regulations: A State-By-State Week In Review
• Lewis Brisbois-Repped Cancer Biotech Plans $25M IPO
• Ex-Worker Says Brandt Finger Scans Violate Ill. Privacy Law
• Real Estate Rumors: Related, Allen & Overy, Welltower
• Arnold & Porter Hires Privacy Pro From Venable
• Activist Investor Elliott Urges Alexion To Consider A Sale
• Actelion Spinoff Loses Bid To Lengthen Patent Term
• Illumina Nears Win In Bid To Block BGI's DNA Product Sales
• Valeant Beats Patent Atty's 'Parasitic' Whistleblower Claims
• COVID Crimes: White Collar Cases To Expect From The Crisis
• Shareholders Say Hemp Co.'s Assets Being 'Robbed' By CEO
• Feds Float Added Charge Against Ex-Theranos CEO
• Prevagen Maker Urges 7th Circ. To Sanction Seller For Appeal
• Goodwin-Led Biotech Pliant Therapeutics Files $86M IPO
• Theranos Offers Defense Lessons For Multi-Agency Probes
• 6th Circ. Opioid Opinion On Federal Rules Helps Cos. In MDLs
• How Law Firms Can Maximize COVID-19 Insurance Coverage
• Younger Attorneys Get Chance At Big Role In Zantac MDL
• The Way Forward For COVID-19 Testing In The US
• Protecting Privilege When Communicating With Contractors
• 4 Firms Steer Cancer-Focused Biotech's $125M IPO Launch 
• Missteps To Avoid In Marketing COVID-19 Antibody Tests
• Adapting Information Governance For The COVID-19 Era
• Aetna Sued Over 'Inexplicable' Refusal To Cover Knee Implant
• Shareholders Ink Deal With Ex-Insys Exec Over Fraud Claims
• J&J Must Face Revived Risperdal Labeling Claims In Calif.
• Payors In Ranbaxy MDL Lose 2 State Claims On Notice Rules
• Fed. Circ. Backs Generic Co.'s IP Win Over Eagle Cancer Drug
• AFL-CIO Chief Keeps Up Attack On DOL's Pandemic Response
• COVID-19 IP Catch-Up: USPTO Gets Busy, Zoom Trial Begins
• Fed. Circ. Weighs Scientists' Ties To Cancer Patents
• Pharma Cos. Escape Claims Drugs Caused Painful Disease
• Virtual Caucuses Can Improve The Mediation Process
• Psychedelic Meds Are Opening A New Frontier For Legal Work
• Apotex Seeks To Revive Hospira Unfair Competition Fight
• How To Assess Accounting Materiality Amid Economic Crisis
• USCIS Should Lower Employment Barriers Amid Pandemic
• 3D Printing And The Shifting Legal Landscape For COVID-19
• Coronavirus-Related TM Filings Will Face Registration Hurdles
• Robbins Geller Must Add Atty Names To Lead OvaScience Suit
• Astellas, Indian Generic Cos. Settle IP Fight Over Bladder Drug
• Real Estate Rumors: Sidewalk Labs, Allakos, CalPERS
• Mo. Medical Pot Regulators Want Fight Over Licenses Tossed
• HHS Official Expects Probe Into Ex-Vaccine Chief's Ouster
• Main Street Lending Program Offers Liquidity With Limits
• Tech Giants In Japan Join Free COVID-19 IP Pledge
• Deals Rumor Mill: Lord & Taylor, Walgreens, Warburg Pincus
• Mont. Cannabis Tax Backers To Begin Gathering Signatures
• What All Attorneys Can Learn From Female Rainmakers
• Apotex To Pay $24M Criminal Fine In DOJ Price-Fixing Case
• M&A Ordinary Course Covenants Amid Extraordinary Times
• No Privilege Shield For Firm Consultant, Express Scripts Says
• Cow Breeding Co. Gets Royalty Tweak Years After IP Verdict
• Alexion Nears $25M Settlement With SEC To End FCPA Probe
• Otsuka Nears Win Against Calif. Abilify Failure-To-Warn Suit
• NJ Court Probes Firing Timing In Pharma Whistleblower Suit
• Roche Rails Against Bid To Void Del. Ruling On IP Rights Buy
• Zetia Buyers Blast Merck's 'Unhinged' Bid To Eject Class Rep
• Fla. Defends Medical Pot Regulations Before State High Court
• Fed. Circ. Says Thermo Fisher Can't Call Dibs On Injector IP
• Fed. Circ. Reveals Why It Didn't Revive Boston Scientific IP
• Set Aside Fund For Pandemic Fight, Obama CDC Chief Says
• 4 Takeaways From 3rd Circ. Classwide Antitrust Injury Ruling
• The 1st COVID-19 Prosecutions Under Defense Production Act
• An Early Look At Congressional Oversight Of The Pandemic
• Restasis Buyers Win Cert. Battle In Allergan Monopoly Case
• Female Justices Tear Into Trump's ACA Birth Control Regs
• PTAB Says Articles Doom Part Of Joint Pain Treatment Patent
• Promoting Lawyer Well-Being Is More Essential Than Ever
• Immunology Co. Unveils Platform And $60M In Investments
• Medical Supplier Gets Early OK For $35M Investor Settlement
• AbbVie Gets FTC Clearance For $63B Allergan Buy
• Judge Says Army Tourniquet Dispute Belongs In Claims Court
• New HIV Antitrust Complaint, Same Problems, Gilead Says
• Kirkland & Ellis Poaches Wachtell M&A Partner In NY
• Livent Stock-Drop Suit Driven By Hindsight, Pa. Judge Told
• HHS Official Ousted For Resisting Virus Drug Wants Job Back
• Amgen Comes Out On Top After Bench Trial Over Cancer Drug
• SEC Says Couple Earned $8.5M Trading Off Neighbor's Intel
• Indivior Can Split IP, Antitrust Claims In Suboxone Fight
• 9th Circ. Told It Can't Order Discovery For Private Arbitration
• Manufacturer Can't Claim Hand Sanitizer Stops Diseases
• Bayer Seeks Win In Suit Over Flintstones 'Complete' Vitamins
• An Employer's Guide To COVID-19 Emergency Planning
• Rep. Neal Calls For 90-Day Hold On Medical Product Duties
• Coronavirus Regulations: A State-By-State Week In Review
• Remote Depositions Bring Ethics Considerations For Lawyers
• Coppertone Buyers Read 'Mineral' Label Wrong, Bayer Says
• Rapid Clinical Developments Increase Insider Trading Risks
• Labor Unions May Set Solid Foundation For Cannabis Industry
• Now May Be A Good Time To Rethink Biometric Regulation
• More Reasons To Redesign The Open Office Post-Pandemic
• Paul Weiss, Cooley Drive $1.41B Deal For Portola Pharma
• Ropes Guides Oberland To $1.05B Health Care Royalty Fund
• Conn. High Court Won't Reverse Boehringer Pradaxa Win
• USPTO Unveils Virus Patent Platform, EPO Extends Deadlines
• Perrigo Follows FTC's Wake With AbbVie Testosterone Suit
• Widow Uninjured By Lost Sperm, Calif. Appeals Court Affirms
• FDA Slaps Tighter Controls On COVID-19 Antibody Tests
• 4th Circ. Says Appeal Of E-Cig Compliance Deadline Is Moot
• Gov't Tells Justices Retroactive IPRs Aren't Theft
• Prevagen Buyer Class Decertified After False Ad Suit Mistrial
• Suboxone Buyers Tell 3rd Circ. Case Is Not Like Lamictal
• 3M Wins Its First NY Injunction Over COVID-19 Price-Gouging
• 7 COVID-19 Compliance Areas For Health, Life Sciences Cos.
• Pa. Biotech Cos. Dispute Ownership Of Gene Therapy IP
• J&J Settles W.Va. AG's Pelvic Mesh Claims For $3.9M
• Latham Guides Israeli Biopharma Targeting $50M In US IPO
• Early Pandemic-Related Shifts We're Seeing In Legal Finance
• Celgene Investors Seek Cert. In Suit Over Drug Disclosures
• 3 Firms Steer Menarini's Stemline Deal Worth Up To $677M
• The Death Of The LSAT
• Design Patents Prove Successful On Enforcement, Defense
• EpiPen Buyers Lost Bid To Depose Ex-Teva CEO In MDL
• ​​​​​​​CDC Urges Meat Plants To Act Quickly To Curb Virus Cases
• FDA Allows Emergency Use Of Gilead Drug For COVID-19
• Genentech Blasts Eli Lilly's $10M Fee Bid For Dropped IP Suit
• Daiichi Told Cancer Drug Patent Fight Must Be Arbitrated
• Mont. Pot Measure Supporters Can't Gather Signatures Online
• Purdue Creditors Get OK For Sackler Bank Subpoenas
• COVID-19 IP Catch-Up: Looming Trials, Jeff Dunham's Dummy
• Taxation With Representation: Weil, White, Kirkland
• DC Circ. Upholds FDA's Abuse-Deterrent Opioid Denial
• Maintaining Product Liability Immunity During The Pandemic
• Sanofi Denies Using Crisis To Obstruct Discovery In Suit
• Dechert's Sheila Birnbaum Talks Remote Work, COVID-19
• 3M Continues Blitz With 4 More Price-Gouging Cases
• Latham Steers As Biotech Firm's $56M IPO Tops Range
• Provisional Patent Applications Are Crucial Amid COVID-19
• Companies Tap Convertible Debt In Droves Amid Pandemic
• Schein Settles Pair Of Investor Suits Over Price-Fixing Claims